Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CFTR2 | RCV000046704 | SCV000245945 | pathogenic | Cystic fibrosis | 2017-03-17 | reviewed by expert panel | research | |
Mendelics | RCV000046704 | SCV000886233 | pathogenic | Cystic fibrosis | 2018-11-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000046704 | SCV002194315 | pathogenic | Cystic fibrosis | 2022-05-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu953Phefs*11) in the CFTR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 53581). This premature translational stop signal has been observed in individual(s) with cystic fibrosis (PMID: 7519167). This variant is present in population databases (rs397508445, gnomAD 0.0009%). |
Institute of Human Genetics, |
RCV000046704 | SCV002574064 | pathogenic | Cystic fibrosis | 2022-09-05 | criteria provided, single submitter | curation | This variant was identified in 6 unrelated patients with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project re-classifying variants in the German Cystic Fibrosis Registry (Muko.e.V.). Link: https://www.muko.info/angebote/qualitaetsmanagement/register/cf-einrichtungen/mukoweb. Criteria applied: PVS1, PS3_SUP, PM2_SUP, PM3_STR, PP4 |
Ambry Genetics | RCV000046704 | SCV002752768 | pathogenic | Cystic fibrosis | 2022-06-15 | criteria provided, single submitter | clinical testing | The c.2859_2890del32 pathogenic mutation, located in coding exon 17 of the CFTR gene, results from a deletion of 32 nucleotides at nucleotide positions 2859 to 2890, causing a translational frameshift with a predicted alternate stop codon (p.L953Ffs*11). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Natera, |
RCV001826649 | SCV002083552 | pathogenic | CFTR-related disorder | 2020-08-10 | no assertion criteria provided | clinical testing |